THR-149 is a Synthetic Peptide owned by Oxurion, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.

THR-149 inhibits plasma kallikrein. PK circulates in plasma as a zymogen, and upon activation cleaves high molecular weight kininogen to generate the vasoactive peptide bradykinin (BK). BK and its metabolites cause the opening of endothelial tight junctions lining blood vessels, resulting in increased vascular permeability. Fluid and macromolecular components of the plasma leak from the vessels into surrounding tissue potentially resulting in edema formation. Activation of PK leads to increased retinal vascular permeability (RVP). By inhibiting kallikrein, RVP is reduced.

The revenue for THR-149 is expected to reach a total of $1.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the THR-149 NPV Report.

THR-149 was originated by Bicycle Therapeutics and is currently owned by Oxurion.

THR-149 Overview

THR-149 is under development for treatment of diabetic macular edema associated with diabetic retinopathy. The therapeutic candidate is administered through intravitreal route. It is developed as sustained release formulation. It is developed by using bicyclic peptide based technology. The therapy consists of bicyclic peptides that inhibit the vascular permeability. It acts by targeting plasma kallikrein.

Oxurion Overview

Oxurion, formerly ThromboGenics, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements with companies such as BioInvent International, Quintiles Outcome Sciences, Bicycle Therapeutics, Galapagos, Parexel, INC Research, Grifols Inc, Patheon, and Alcon. It has a presence in Belgium, Ireland and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.

The company reported revenues of (Euro) EUR1.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 45.7% over FY2020. The operating loss of the company was EUR28.5 million in FY2021, compared to an operating loss of EUR28.6 million in FY2020. The net loss of the company was EUR29.2 million in FY2021, compared to a net loss of EUR28 million in FY2020.

Quick View – THR-149

Report Segments
  • Innovator
Drug Name
  • THR-149
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.